Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 2019: Clinical Data Update on TWILIGHT and TWILIGHT-ACS
Author(s): Marc P Bonaca , Roxana Mehran Added: 4 years ago
Dr Marc P Bonaca (University of Colorado, Aurora, US) and Prof Roxana Mehran (Mount Sinai Hospital, New York, US) discuss the latest Clinical Data Update on TWILIGHT and TWILIGHT-ACS. This video is a segment from a wider wrap-up of data presented at AHA 2019 on Antithrombotics. The full discussion can be viewed at https://www.radcliffecardiology.com/AHA-2019-Clinical-Data-Update-on-Ant... … View more

Anticoagulation

MI/ACS
ACC 2020: Update from the TWILIGHT Study — Prof Dominick J Angiolillo
Author(s): Dominick J Angiolillo Added: 4 years ago
Prof Dominick J Angiolillo (University of Florida College of Medicine-Jacksonville, Jacksonville, FL, US) discusses the findings of the TWILIGHT study. The TWILIGHT study compared the use of ticagrelor alone versus ticagrelor and aspirin together. Questions : 1. Can you remind us of the TWILIGHT study and what it showed? 2. Why have you conducted this sub-analysis in high risk patients with… View more

Anticoagulation

Prevention & Chronic Conditions
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
Author(s): George D Dangas Added: 2 years ago
Dr George Dangas (Mount Sinai Hospital, New York, NY, US) discusses the results of the TWILIGHT-Stent trial, presented at ESC 2021. This study examined the incidence of ischemic and bleeding events in patients treated with contemporary drug-eluting stents over 3-15 months. This trial also examined ticagrelor monotherapy vs ticagrelor with aspirin. Questions: 1. What were the main aims of… View more

Anticoagulation

Intervention
TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
Author(s): Davide Cao Added: 2 years ago
Dr Davide Cao (Icahn School of Medicine at Mount Sinai, US) discusses the key results and impact on clinical practice of the pre-specified analysis of the TWILIGHT trial presented at ESC Congress 2021. TWILIGHT-HBR evaluated the effects of ticagrelor monotherapy versus ticagrelor (Brilinta) plus aspirin on bleeding and ischemic outcomes in a contemporary ARC-defined HBR population undergoing… View more

Anticoagulation

Intervention
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
Author(s): Johny Nicolas , Usman Baber , Roxana Mehran Added: 3 years ago
Seminal clinical trials conducted in the balloon angioplasty and bare metal stent era established the superiority of dual antiplatelet therapy (DAPT) as compared with aspirin monotherapy or anticoagulation with respect to the prevention of thrombotic events.1,2 Other studies found that the benefits of DAPT are durable for at least 1 year and extend to patients with acute coronary syndromes.3–5… View more

Anticoagulation
ESC 2021: Late-breaking Science Video Collection
Author(s): George D Dangas , Adrian P Banning , Davide Cao , et al Added: 2 years ago
Our regular review seriesView from the Thoraxcenterhosted by Prof Nicolas Van MieghemandDr Joost Daemen(Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data. For a deeper dive into key clinical trial data,Dr Harriette Van Spall(McMaster University, Hamilton, CA) interviewed principal investigators on their studies… View more

Anticoagulation

Standards & Guidelines
Research Area(s) / Expertise: Job title: Associate Professor of Medicine
Personal History Dr. Usman Baber is a Cardiologist and an Interventional Cardiologist based in Oklahoma City, Oklahoma.1 Academic History Dr. Baber earned his bachelor's degree in Biochemistry from Rice University in 1999 and graduated as a Doctor of Medicine from UT Southwestern Medical Center in 2004. During his fellowship training he also earned a master’s degree in biostatistics… View more
Dominick J Angiolillo
Research Area(s) / Expertise:

Thrombosis, embolism & bleeding

Intervention

Coronary Artery Disease and Myocardial Infarction

 Job title: Professor & Chief
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology.Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology. In 2004, Dr… View more
Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention
Author(s): Dimitrios Alexopoulos , Charalampos Varlamos , Despoina-Rafailia Benetou Added: 3 years ago
Complex percutaneous coronary intervention (PCI) usually refers to procedures that include bifurcation with two stents implanted, the treatment of three or more lesions, the implantation of three or more stents, total stent length >60 mm, or a chronic total occlusion (CTO).1 However, as there is no universal definition, other features, such as left main (LM) or proximal left anterior… View more

Intervention
Type and Duration of Antithrombotic Treatment in Complex PCI
Author(s): Despoina-Rafailia Benetou , Charalampos Varlamos , Christos Pappas , et al Added: 2 years ago

Anticoagulation